Bernstein CN, et al. World gastroenterology organisation global guidelines inflammatory bowel disease: update august 2015. J Clin Gastroenterol. 2016;50(10):803–18.

Article  PubMed  Google Scholar 

Denson LA, et al. Challenges in IBD research: precision medicine. Inflamm Bowel Dis. 2019;25(Suppl 2):S31–9.

Article  PubMed  Google Scholar 

Tabib NSS, et al. Big data in IBD: big progress for clinical practice. Gut. 2020;69(8):1520–32.

Article  CAS  Google Scholar 

Alatab S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.

Article  Google Scholar 

Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63.

Article  PubMed  Google Scholar 

Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088–103.

Article  CAS  PubMed  Google Scholar 

Dignass A, et al. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ. 2020;23(4):415–27.

Article  PubMed  Google Scholar 

da Silva BC, et al. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–67.

Article  PubMed  PubMed Central  Google Scholar 

Crohn's & Colitis Foundation of America. The facts about Inflammatory Bowel Diseases. 2014.

Cohen R, et al. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447–56.

Article  PubMed  Google Scholar 

Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020;18(6):1252–60.

Article  PubMed  Google Scholar 

Matos R, et al. Quality of life in patients with inflammatory bowel disease: the role of positive psychological factors. Health Psychol Behav Med. 2021;9(1):989–1005.

Article  PubMed  PubMed Central  Google Scholar 

Mayo Clinic. Crohn's disease. 2020 [cited 2022 February 15]; Available from: https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304

Cleveland Clinic. Ulcerative Colitis. 2020 [cited 2022 February 15]; Available from: https://my.clevelandclinic.org/health/diseases/10351-ulcerative-colitis

Click B, Binion DG, Anderson AM. Predicting costs of care for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(3):393–5.

Article  PubMed  Google Scholar 

Annese V, et al. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol. 2021;14:17562848211065328.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ehrenberg R., et al. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6): 758–765

van der Valk ME, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63(1):72–9.

Article  PubMed  Google Scholar 

Lichtenstein, GR, et al. Lifetime economic burden of Crohn's disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4): 889–897 e10.

Gibson TB, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261–2122.

Article  PubMed  Google Scholar 

Rubin DT, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–55.

Article  CAS  PubMed  Google Scholar 

Long MD, et al. Retrospective database analysis: dose escalation and adherence in patients initiating biologics for ulcerative colitis. Dig Dis. 2021;40(5):553–64.

Article  PubMed  Google Scholar 

Guberna L., et al. Frequency and effectiveness of empirical anti-tnf dose intensification in inflammatory bowel disease: systematic review with meta-analysis. J Clin Med, 2021. 10(10).

Khan S, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.

PubMed  Google Scholar 

Zittan E, Gralnek IM, Berns MS. The new proactive approach and precision medicine in Crohn's disease. Biomedicines. 2020;8(7).

Sanchez-Hernandez JG, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma C, et al. Ustekinumab effective for maintaining clinical response in refractory moderate-to-severe Crohn’s disease: a multicentre cohort study [abstract]. In: Journal of the Canadian Association of Gastroenterology. Oxford University Press; 2018. p. 182–4.

Google Scholar 

Eberl A, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54(6):718–25.

Article  CAS  PubMed  Google Scholar 

Yadav A, et al. Dose escalation (Q4) of ustekinumab should be considered for Crohn's disease patients who fail standard dosing [abstract]. In: Inflammatory bowel diseases. 2020, Crohn’s & Colitis Foundation and the AGA Institute. p. S72–S73.

Battat R, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2017; 15(9): 1427–1434 e2.

Heron V, et al. Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response. J Crohns Colitis. 2019;13:S379–80.

Article  Google Scholar 

Olmedo-Martín R, et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study. J Crohns Colitis. 2021;15:S467–8.

Article  Google Scholar 

Mateos B, et al. Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn’s Disease patients. J Crohns Colitis. 2021;15:S533–4.

Article  Google Scholar 

Ma C, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833–9.

Article  PubMed  Google Scholar 

Khorrami S, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–9.

Article  PubMed  Google Scholar 

Chaparro M, et al. Long-term durability and safety of Ustekinuman (UST) in patients with active Crohn's disease (CD) in real life: SUSTAIN study [abstract]. In: 28th United European Gastroenterology Week. 2020: Virtual. 407–408.

Chaparro M, et al. Effectiveness and safety of Ustekinumab (UST) in patients with active Crohn's disease (CD) in real life: SUSTAIN study [abstract]. In: 28th United European Gastroenterology Week. 2020: Virtual. 406–407.

Truyens M, et al. Efficacy of Ustekinumab intensification and re-induction in Crohn’s disease patients with insufficient or loss of response. Unit Eur Gastroenterol J. 2019;7(8 suppl): 645–645

Glassner K, et al. Low levels of ustekinumab despite dose escalation is a risk factor for surgery. Am Coll Gastroenterol. 2019;114:S405.

Google Scholar 

Ramaswamy PK, et al. MO1869 Efficacy of dose intensification of ustekinumab in Crohn's disease. Gastroenterology. 2020;S-956.

Sipponen T, et al. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland. Scand J Gastroenterol. 2021;56(6):661–70.

Article  CAS  PubMed  Google Scholar 

Biemans VBC, et al. Vedolizumab for inflammatory bowel disease: two-year results of the initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study. Clin Pharmacol Ther. 2020;107:1189–99.

Article  CAS  PubMed  Google Scholar 

Biemans V, et al. Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study. J Crohns Colitis. 2019;13:S363–4.

Article  Google Scholar 

Attauabi M, et al. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease—a real-world two-center cohort study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1): e709-e718.

Attauabi M, et al. Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease—a real-world two-center cohort study [abstract]. In: 29th United European Gastroenterology Week. 2021:550.

Shivashankar R, et al. Effect of vedolizumab dose escalation on recapturing response in patients with inflammatory bowel disease. Gastroenterol. 2017;152(5).

Mendoza Ladd AH, et al. Sa1086 Dose Escalation of Vedolizumab From Every 8 Weeks to Every 4 or 6 Weeks Enables Patients With Inflammatory Bowel Disease to Recapture Response. In: Gastroenterology. 2016:S235-S236.

Iborra M, et al. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Gastroenterología y Hepatología (English Edition). 2018;41(9):535–43.

Article  Google Scholar 

Iborra M, et al. Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients. J Crohns Colitis. 2018;12:S472–3.

Article  Google Scholar 

Dulai PS, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–55.

Article  CAS  PubMed  Google Scholar 

Amiot A, et al. One-year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–21.

Article  CAS  PubMed  Google Scholar 

Amiot A, et al. Three-year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50(1):40–53.

Article  CAS  PubMed  Google Scholar 

Srinivasan A, et al. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1342–52.

Article  CAS  PubMed  Google Scholar 

Suzuki T, et al. Adalimumab dose escalation therapy is effective in refractory Crohn’s disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment. Case Rep Gastroenterol. 2019;13(1):37–49.

Article  PubMed  PubMed Central  Google Scholar 

Olivares D, et al. Differences in the need for Adalimumab dose optimization between Crohn’s disease and Ulcerative Colitis. Rev Esp Enferm Dig. 2019;111(11):846–51.

PubMed